Focused On-demand Library for Myc box-dependent-interacting protein 1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

O00499

UPID:

BIN1_HUMAN

Alternative names:

Amphiphysin II; Amphiphysin-like protein; Box-dependent myc-interacting protein 1; Bridging integrator 1

Alternative UPACC:

O00499; O00297; O00545; O43867; O60552; O60553; O60554; O60555; O75514; O75515; O75516; O75517; O75518; Q659B7; Q92944; Q99688

Background:

Myc box-dependent-interacting protein 1, also known as Amphiphysin II, plays a crucial role in membrane dynamics, including plasma membrane curvature and endocytosis regulation. It is essential in muscle cells for T-tubules formation, vital for muscle contraction. Additionally, it influences amyloid-beta production and may regulate MYC activity, impacting cell proliferation. Its actin bundling activity further underscores its importance in cellular structure maintenance.

Therapeutic significance:

Given its involvement in Myopathy, centronuclear, 2, a disorder characterized by progressive muscle weakness, understanding the role of Myc box-dependent-interacting protein 1 could open doors to potential therapeutic strategies. Its regulatory functions in membrane dynamics and cell proliferation make it a promising target for addressing the underlying mechanisms of this congenital muscle disorder.